source
- Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.
- Anthropic appoints former Genentech scientist Nathan Frey to lead drug discovery after acquiring Coefficient BioAnthropic, the AI company, recently bought biotech startup Coefficient Bio. Following the acquisition, the startup’s founder Nathan Frey, who previously worked at Genentech on machine‑learning proj…